{
  "index": 639,
  "prompt": "\nGiven the following scenario, first consider the actors and stakeholders involved then extrapolate and present as a timeline how the situation might evolve. \nConsider as many multiple possibilities based on possible responses which are to be represented as branches on this timeline. \n\nMake sure that the timeline generated are of **HIGH QUALITY** as defined by the following criteria\n* Plausibility: Economic, financial and political plausibility of each path on the timeline \n    * High: Events are strongly supported by current macro data, institutional knowledge, and have strong analogs in history or system models (e.g., “monetary tightening leads to recession, triggering a political backlash”)\n    * Low: Contains major violations of cause-effect logic, timing, or real-world behavior (e.g., hyperinflation causes interest rate cuts during a currency collapse)\n* Novelty: Creativity/originality in the nodes and paths, are they something you may have overlooked?\n    * High: Demonstrates expert-level creative reasoning. Identifies counterintuitive paths, rare risks, or hidden feedback loops. May challenge conventional wisdom in a grounded way (e.g., “trade war accelerates global realignment of semiconductors via Middle East sovereign wealth capital”). Could lead to edge in investment or policy thinking.\n    * Low: Timeline is linear, obvious, or closely tracks past headlines or boilerplate analysis. No creative branching or exploration.\n* Elaboration: How specific and refined are the occurrences represented by the nodes?\n    * High: Timeline reads like a mini-case study. Each node could stand alone as an actionable insight. Paths show feedback loops, strategic responses, and sector-level granularity (e.g., “Volkswagen reallocates $1.2B R&D from EVs to hybrid tech in response to rare earth prices”). Truly investment-grade thinking.\n    * Low: Nodes are generic (e.g., “market reacts”, “tensions rise”) with no detail on mechanisms, actors, or consequences. Lacks causal clarity.\n* Actionable: Can this timeline inform specific investment actions or hedging strategies?\n    * High: Timeline includes sector impacts, asset class consequences, or opportunities (e.g., “short EU auto suppliers”, “long U.S. rail freight”)\n    * Low: Insightful narrative, but no clear link to tradable instruments or positioning ideas\n\nKeep to the output format below where ascii is used to represent the timeline as a tree. \n\n[Example of Scenario]\nWASHINGTON/DETROIT, April 29 (Reuters) - U.S. President Donald Trump signed a pair of orders to soften the blow of his auto tariffs on Tuesday with a mix of credits and relief from other levies on materials, and his trade team touted its first deal with a foreign trading partner.\nThe developments helped eased some investor worries about the erratic trade policies of Trump as the president visited Michigan, a cradle of the U.S. auto industry, just days before a fresh set of 25% import taxes was set to kick in on automotive components.\n\n[Example of Output]\n{\n  \"id\": \"T0\",\n  \"title\": \"Initial Event\",\n  \"description\": \"German inflation data released at 2.2%\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"ECB maintains dovish stance\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB maintains dovish stance, keeps rates low\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"German banks increase lending\",\n          \"description\": \"German banks benefit from low rates, increase lending\"\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Euro weakens\",\n          \"description\": \"Euro weakens, boosting exports\"\n        },\n        {\n          \"id\": \"T1A1.3\",\n          \"title\": \"Moderate industrial growth\",\n          \"description\": \"German industry reports moderate growth\"\n        },\n        {\n          \"id\": \"T1A1.4\",\n          \"title\": \"Bundesbank caution\",\n          \"description\": \"Bundesbank signals caution on inflation\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Industry adapts to inflation\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Companies pass on higher costs; unions request wage hikes; consumer shifts emerge\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Markets stabilize\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Eurozone growth outlook improves; German stocks outperform\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Global growth stabilizes\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Global trade rebounds; emerging markets benefit\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"New normal\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Stable growth across EU/US; ECB remains dovish\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"ECB tightens monetary policy\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB tightens policy in response to inflation\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Euro strengthens\",\n          \"description\": \"Euro strengthens, hurting exports\"\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Industrial slowdown\",\n          \"description\": \"German industry reports slower growth\"\n        },\n        {\n          \"id\": \"T1A2.3\",\n          \"title\": \"Bundesbank warns\",\n          \"description\": \"Bundesbank warns of inflation risks\"\n        },\n        {\n          \"id\": \"T1A2.4\",\n          \"title\": \"Consumers cut back\",\n          \"description\": \"German consumers cut back on spending\",\n          \"children\": [\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Industry opposes ECB policy\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Job cuts, political backlash, delayed consumption\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"Markets unstable\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Growth outlook declines; ECB remains hawkish\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Global recession risk rises\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Trade slows; emerging markets struggle\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Global downturn\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Recession conditions persist; ECB maintains rate hikes\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n\n[Given Scenario]\nThe report forecasts the type 1 diabetes (T1D) therapeutics market to grow from approximately $2.83 billion in 2023 to $9.91 billion by 2033, at a compound annual growth rate (CAGR) of 13.3% over the forecast period. The major drivers of T1D market growth are the increase in the prescription of rapid-acting insulins, the launch of several oral and injectable agents, particularly immunomodulatory therapies, and the increase in the global prevalence of T1D. \n\nThe major barriers to the growth of the T1D market are the high price of certain insulins and immunomodulatory agents, patent expiries allowing for further biosimilar and generic erosion, and the high failure rate of clinical trials developing disease-modifying therapeutics. The report also highlights the unmet needs in the T1D market, including the urgent need for disease-modifying therapies, avoiding hypoglycemic episodes, improving compliance, and reducing the financial cost of T1D management.\n\nThe report provides a comprehensive analysis of the T1D market, including the current and future market competition, key industry drivers, restraints, and challenges. It also includes a pipeline assessment of emerging trends and mechanisms of action under development for T1D treatment, with the most promising candidates in late-stage development profiled.\n\nThe report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the T1D market through 2033. The report also includes a competitive assessment of the T1D market, with key players such as Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, Boehringer Ingelheim, Amgen, and others.\n\nThe report highlights the potential for Amgen to benefit from the growth of the T1D market, particularly with its involvement in the development of immunomodulatory therapies. However, the report also notes that Amgen faces competition from other players in the market, including Novo Nordisk, Eli Lilly, and Sanofi.\n[Output in JSON]\n",
  "response": "```json\n{\n  \"id\": \"T0\",\n  \"title\": \"2023 T1D Market Report Released\",\n  \"description\": \"A comprehensive report projects the T1D therapeutics market to grow from $2.83B in 2023 to $9.91B by 2033, driven by increased insulin prescriptions, new therapies, and rising prevalence.\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"Major Pharma Players Expand R&D in T1D\",\n      \"date_range\": \"2024-2025\",\n      \"description\": \"Key companies like Amgen, Novo Nordisk, and Eli Lilly increase investment in R&D for immunomodulatory and disease-modifying therapies.\",\n      \"children\": [\n        {\n          \"id\": \"T2A1\",\n          \"title\": \"Amgen Advances Immunomodulatory Pipeline\",\n          \"date_range\": \"2026\",\n          \"description\": \"Amgen initiates Phase III trials for its leading immunomodulatory therapy, targeting T1D disease modification.\",\n          \"children\": [\n            {\n              \"id\": \"T3A1\",\n              \"title\": \"Positive Phase III Results\",\n              \"date_range\": \"2027\",\n              \"description\": \"Amgen's therapy shows significant efficacy in delaying T1D progression, leading to FDA approval.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A1\",\n                  \"title\": \"Market Leadership Secured\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Amgen captures 25% market share in T1D therapeutics, driving stock up 30%.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5A1\",\n                      \"title\": \"Expansion into Emerging Markets\",\n                      \"date_range\": \"2029-2030\",\n                      \"description\": \"Amgen leverages its success to enter emerging markets, further increasing its revenue stream.\"\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A2\",\n              \"title\": \"Phase III Failure\",\n              \"date_range\": \"2027\",\n              \"description\": \"Amgen's immunomodulatory therapy fails to meet primary endpoints, leading to stock decline.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A2\",\n                  \"title\": \"Shift to Alternative Therapies\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Amgen reallocates R&D funds to alternative therapeutic approaches, such as gene therapy.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5A2\",\n                      \"title\": \"Potential Breakthrough\",\n                      \"date_range\": \"2030\",\n                      \"description\": \"New gene therapies show promise, positioning Amgen for a late-stage success.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2A2\",\n          \"title\": \"Novo Nordisk Launches Next-Gen Insulin\",\n          \"date_range\": \"2025\",\n          \"description\": \"Novo Nordisk introduces a new rapid-acting insulin with improved hypoglycemia profiles, gaining significant market traction.\",\n          \"children\": [\n            {\n              \"id\": \"T3A3\",\n              \"title\": \"Increased Prescription Rates\",\n              \"date_range\": \"2026-2027\",\n              \"description\": \"Doctors prefer Novo's insulin, boosting sales by 20% annually.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A3\",\n                  \"title\": \"Competitive Pressure on Peers\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Competitors like Eli Lilly and Sanofi accelerate their own insulin innovations to retain market share.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5A3\",\n                      \"title\": \"Market Consolidation\",\n                      \"date_range\": \"2030\",\n                      \"description\": \"Mergers and acquisitions occur as companies seek to strengthen their therapeutic portfolios.\"\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A4\",\n              \"title\": \"Regulatory Scrutiny on Pricing\",\n              \"date_range\": \"2027\",\n              \"description\": \"Governments in 7MM implement price controls on insulin to address affordability concerns.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A4\",\n                  \"title\": \"Profit Margins Affected\",\n                  \"date_range\": \"2028-2029\",\n                  \"description\": \"Novo Nordisk adjusts pricing strategies, focusing on volume growth to maintain revenue.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T5A4\",\n                      \"title\": \"Investment Shift to Generics\",\n                      \"date_range\": \"2030\",\n                      \"description\": \"Investors favor companies investing in biosimilars and generics to capitalize on price-sensitive markets.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"Patent Expirations and Biosimilar Entry\",\n      \"date_range\": \"2025-2026\",\n      \"description\": \"Several major T1D therapeutics face patent expirations, leading to biosimilar and generic competition.\",\n      \"children\": [\n        {\n          \"id\": \"T2A3\",\n          \"title\": \"Generic Insulin Market Surge\",\n          \"date_range\": \"2027\",\n          \"description\": \"Generic insulins enter the market, reducing prices by 30% and increasing accessibility.\",\n          \"children\": [\n            {\n              \"id\": \"T3A5\",\n              \"title\": \"Increased Adoption in Developing Markets\",\n              \"date_range\": \"2028\",\n              \"description\": \"Lower prices make insulin more accessible in developing regions, expanding the overall market size.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A5\",\n                  \"title\": \"Revenue Diversification\",\n                  \"date_range\": \"2029\",\n                  \"description\": \"Original manufacturers diversify revenue streams through premium product lines and services.\"\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A6\",\n              \"title\": \"Market Saturation\",\n              \"date_range\": \"2028\",\n              \"description\": \"Intense competition leads to market saturation, forcing companies to innovate or exit segments.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A6\",\n                  \"title\": \"Shift to Specialty Therapies\",\n                  \"date_range\": \"2030\",\n                  \"description\": \"Pharma companies focus on specialty and personalized therapies to maintain profitability.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2A4\",\n          \"title\": \"Biosimilar Regulatory Enhancements\",\n          \"date_range\": \"2026\",\n          \"description\": \"Regulators streamline approval processes for biosimilars, accelerating market entry.\",\n          \"children\": [\n            {\n              \"id\": \"T3A7\",\n              \"title\": \"Faster Market Penetration\",\n              \"date_range\": \"2027\",\n              \"description\": \"Biosimilars achieve faster penetration, increasing competition and lowering overall market prices.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A7\",\n                  \"title\": \"Innovation Pressure\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Original innovators invest more in R&D to develop next-generation therapies to stay ahead.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A3\",\n      \"title\": \"Breakthrough in Disease-Modifying Therapies\",\n      \"date_range\": \"2025\",\n      \"description\": \"A major breakthrough in disease-modifying T1D therapy is achieved, significantly altering the treatment landscape.\",\n      \"children\": [\n        {\n          \"id\": \"T2A5\",\n          \"title\": \"Rapid Approval and Adoption\",\n          \"date_range\": \"2026\",\n          \"description\": \"The breakthrough therapy receives expedited FDA and EMA approval, leading to swift adoption by healthcare providers.\",\n          \"children\": [\n            {\n              \"id\": \"T3A8\",\n              \"title\": \"Dominance of Innovator\",\n              \"date_range\": \"2027\",\n              \"description\": \"The innovator company secures a dominant market position, with minimal competition initially.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A8\",\n                  \"title\": \"High Investment Returns\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Investors see significant returns from the innovator's stock, attracting more capital to the sector.\"\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A9\",\n              \"title\": \"Entry of Competitors\",\n              \"date_range\": \"2027\",\n              \"description\": \"Other pharma companies accelerate their own R&D to develop competing disease-modifying therapies.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A9\",\n                  \"title\": \"Therapeutic Diversification\",\n                  \"date_range\": \"2029\",\n                  \"description\": \"Market sees a variety of disease-modifying options, fostering personalized treatment approaches.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2A6\",\n          \"title\": \"Health Economics Impact\",\n          \"date_range\": \"2026\",\n          \"description\": \"Cost-effectiveness analyses show long-term savings from disease-modifying therapies, influencing insurance coverage.\",\n          \"children\": [\n            {\n              \"id\": \"T3A10\",\n              \"title\": \"Increased Insurance Reimbursement\",\n              \"date_range\": \"2027\",\n              \"description\": \"Insurance companies expand coverage for disease-modifying therapies, boosting patient access.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A10\",\n                  \"title\": \"Broader Market Adoption\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Higher reimbursement rates lead to widespread adoption, driving market growth.\"\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A11\",\n              \"title\": \"Policy Incentives for Innovation\",\n              \"date_range\": \"2027\",\n              \"description\": \"Governments introduce incentives for developing disease-modifying therapies, further accelerating innovation.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A11\",\n                  \"title\": \"Surge in R&D Investments\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Pharma companies increase R&D budgets, leading to a surge in innovative therapies entering the pipeline.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A4\",\n      \"title\": \"Regulatory and Pricing Pressure\",\n      \"date_range\": \"2024-2025\",\n      \"description\": \"Heightened focus on the high cost of T1D therapies leads to regulatory and pricing pressures in key markets.\",\n      \"children\": [\n        {\n          \"id\": \"T2A7\",\n          \"title\": \"Introduction of Price Caps\",\n          \"date_range\": \"2026\",\n          \"description\": \"Regulators in the US and Europe implement price caps on insulins and immunomodulatory agents.\",\n          \"children\": [\n            {\n              \"id\": \"T3A12\",\n              \"title\": \"Revenue Pressure on Innovators\",\n              \"date_range\": \"2027\",\n              \"description\": \"Price caps significantly reduce profit margins for original manufacturers.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A12\",\n                  \"title\": \"Cost-Cutting Measures\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Companies implement cost-cutting measures, including workforce reductions and streamlined operations.\"\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A13\",\n              \"title\": \"Shift to Value-Based Pricing\",\n              \"date_range\": \"2027\",\n              \"description\": \"Pharma companies adopt value-based pricing models linked to therapeutic outcomes.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A13\",\n                  \"title\": \"Enhanced Therapy Efficacy\",\n                  \"date_range\": \"2029\",\n                  \"description\": \"Focus on improving therapy efficacy and patient outcomes to justify pricing.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2A8\",\n          \"title\": \"Reimbursement Reevaluation\",\n          \"date_range\": \"2026\",\n          \"description\": \"Insurance providers reevaluate reimbursement strategies, emphasizing cost-effectiveness.\",\n          \"children\": [\n            {\n              \"id\": \"T3A14\",\n              \"title\": \"Adoption of Biosimilars\",\n              \"date_range\": \"2027\",\n              \"description\": \"Greater adoption of biosimilars as cost-effective alternatives to branded therapies.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A14\",\n                  \"title\": \"Market Share Redistribution\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Original manufacturers lose market share to biosimilar competitors, affecting revenue streams.\"\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A15\",\n              \"title\": \"Premium for Innovative Therapies\",\n              \"date_range\": \"2027\",\n              \"description\": \"Insurance providers offer premium coverage for innovative, disease-modifying therapies.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A15\",\n                  \"title\": \"Increased Accessibility for Advanced Therapies\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Patients gain better access to cutting-edge treatments, driving demand for premium therapies.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A5\",\n      \"title\": \"Technological Innovations in T1D Management\",\n      \"date_range\": \"2024-2025\",\n      \"description\": \"Advancements in digital health and wearable technologies enhance T1D management and patient compliance.\",\n      \"children\": [\n        {\n          \"id\": \"T2A9\",\n          \"title\": \"Integration of AI in Treatment Personalization\",\n          \"date_range\": \"2026\",\n          \"description\": \"AI-driven platforms provide personalized treatment regimens, improving patient outcomes and compliance.\",\n          \"children\": [\n            {\n              \"id\": \"T3A16\",\n              \"title\": \"Partnerships with Tech Firms\",\n              \"date_range\": \"2027\",\n              \"description\": \"Pharma companies partner with tech firms to integrate AI solutions into their therapeutic offerings.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A16\",\n                  \"title\": \"Enhanced Therapy Effectiveness\",\n                  \"date_range\": \"2028\",\n                  \"description\": \"Personalized treatments lead to higher efficacy rates, increasing patient satisfaction and adherence.\"\n                }\n              ]\n            },\n            {\n              \"id\": \"T3A17\",\n              \"title\": \"Data-Driven Insights\",\n              \"date_range\": \"2027\",\n              \"description\": \"Continuous data collection from wearables provides insights for further therapeutic improvements.\",\n              \"children\": [\n                {\n                  \"id\": \"T4A17\",\n                  \"title\": \"Iterative Therapy Enhancements\",\n                  \"date_range\": \"2029\",\n                  \"description\": \"Therapies are iteratively enhanced based on real-world data, maintaining competitiveness.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T2A10\",\n          \"title\": \"Adoption of Continuous Glucose Monitoring (CGM)\",\n          \"date_range\": \"2026\",\n          \"description\": \"Widespread adoption of CGM devices reduces hypoglycemic episodes and improves disease management.\",\n          \"children\": [\n            {\n              \"id\": \"T3A18\",\n              \"title\": \"Reduction in Emergency Visits\",\n              \"date_range\": \"2027\",\n              \"description\": \"Better glucose monitoring leads to fewer emergency medical visits, lowering overall healthcare costs.\"\n            },\n            {\n              \"id\": \"T3A19\",\n              \"title\": \"Increased Demand for CGM-Compatible Therapies\",\n              \"date_range\": \"2027\",\n              \"description\": \"Therapies that integrate seamlessly with CGM data become more attractive to both patients and providers.\"\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A6\",\n      \"title\": \"High Failure Rate in Clinical Trials\",\n      \"date_range\": \"2024-2025\",\n      \"description\": \"Attempts to develop disease-modifying T1D therapies face high failure rates, posing a significant barrier to market growth.\",\n      \"children\": [\n        {\n          \"id\": \"T2A11\",\n          \"title\": \"Increased R&D Costs\",\n          \"date_range\": \"2026\",\n          \"description\": \"High failure rates drive up R&D costs, leading companies to seek partnerships or mergers to share risks.\",\n          \"children\": [\n            {\n              \"id\": \"T3A20\",\n              \"title\": \"Strategic Alliances Formed\",\n              \"date_range\": \"2027\",\n              \"description\": \"Pharma companies form alliances with biotech firms to pool resources and expertise, enhancing success rates.\"\n            },\n            {\n              \"id\": \"T3A21\",\n              \"title\": \"Focus on Early-Stage Research\",\n              \"date_range\": \"2027\",\n              \"description\": \"Companies invest more in early-stage research and preclinical studies to mitigate late-stage failures.\"\n            }\n          ]\n        },\n        {\n          \"id\": \"T2A12\",\n          \"title\": \"Shift to Precision Medicine\",\n          \"date_range\": \"2026\",\n          \"description\": \"Focus shifts towards precision medicine approaches, targeting specific patient subgroups to improve trial success rates.\",\n          \"children\": [\n            {\n              \"id\": \"T3A22\",\n              \"title\": \"Improved Clinical Outcomes\",\n              \"date_range\": \"2028\",\n              \"description\": \"Precision therapies demonstrate better clinical outcomes, increasing approval rates and market acceptance.\"\n            },\n            {\n              \"id\": \"T3A23\",\n              \"title\": \"Regulatory Support for Precision Trials\",\n              \"date_range\": \"2027\",\n              \"description\": \"Regulators provide guidelines and support for precision medicine trials, facilitating smoother approval processes.\"\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n```",
  "processing_time": 66.5467598438263,
  "estimated_prompt_tokens": 2318,
  "response_tokens": 3887
}